O. Kostek Et Al. , "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, pp.115-122, 2019
Kostek, O. Et Al. 2019. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1 , 115-122.
Kostek, O., Hacioglu, M. B., Sakin, A., Demir, T., Sari, M., Ozkul, O., ... ARAZ, M.(2019). Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, 115-122.
Kostek, Osman Et Al. "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, 115-122, 2019
Kostek, Osman Et Al. "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, pp.115-122, 2019
Kostek, O. Et Al. (2019) . "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, pp.115-122.
@article{article, author={Osman Kostek Et Al. }, title={Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2019, pages={115-122} }